NCT02386033

Brief Summary

ABSTARCT Background: Atorvastatin is an inhibitor of 3-hydroxy-2-methyl-glutaryl coenzyme A reductase. Lately, it has shown to have anti-inflammatory and bone stimulatory effects. The aim of the current study is to explore the effectiveness of 1.2% atorvastatin (ATV) as an adjunct to scaling and root planning (SRP) in the treatment of mandibular degree II furcation defects. Method: A total of sixty subjects were randomly assigned to two treatment groups. 1. SRP plus placebo gel 2. SRP plus 1.2% ATV gel. Clinical parameters like probing depth (PD), relative vertical clinical attachment level (RVCAL) , relative horizontal clinical attachment level (RHCAL), modified sulcus bleeding index (mSBI) and site specific plaque index were recorded at baseline and then at 3, 6 and 9 months. The radiological assessment of bone defect fill was done at 6 and 9 months, using a computer-aided software.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Nov 2013

Shorter than P25 for phase_2

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2013

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2014

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

November 30, 2014

Completed
3 months until next milestone

First Posted

Study publicly available on registry

March 11, 2015

Completed
Last Updated

March 11, 2015

Status Verified

November 1, 2014

Enrollment Period

8 months

First QC Date

November 30, 2014

Last Update Submit

March 5, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • amount of bone fill

    baseline to 9 months

Secondary Outcomes (5)

  • change in Relative vertical clinical attachment level

    baseline to 9 months

  • change in RHCAL (relative horizontal clinical attachment level)

    baseline to 9 months

  • change in probing depth

    baseline to 9 months

  • change in site specific plaque index

    baseline to 9 months

  • change in modified sulcus bleeding index

    baseline to 9 months

Study Arms (2)

SRP plus placebo

PLACEBO COMPARATOR

SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket

Drug: Placebo Gel

SRP plus Atorvastatin

ACTIVE COMPARATOR

SRP was done for all the subjects. Atorvastatin was delivered in the pocket subgingivally

Drug: Atorvastatin (ATV)

Interventions

After SRP, ATV gel was delivered subgingivally into the pocket

Also known as: ATV gel
SRP plus Atorvastatin

After SRP, placebo gel was delivered subgingivally into the pocket

SRP plus placebo

Eligibility Criteria

Age30 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • lower first molars demonstrating a probing pocket depth of 5 mm and horizontal probing depth of 3 mm following phase 1 therapy, with furcation defects (degree II) present bucally in asymptomatic, vital lower first molars, with a furcation radiolucency on a periapical radiograph of the molars.

You may not qualify if:

  • patients with systemic diseases like cardiovascular disease
  • diabetes or HIV infection or on medications like corticosteroids which may impede the healing in periodontal tissues.
  • pregnant/lactating females
  • tobacco users
  • alcoholics
  • patients with unsatisfactory oral hygiene (plaque index greater than 1.5)
  • teeth having gingival recession, caries involving pulp, intrabony defect present interproximally, grade 2/3 mobility
  • Furthermore, patients allergic to ATV or other statins or those taking ATV/other statins systemically were excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Chronic Periodontitis

Interventions

Atorvastatin

Condition Hierarchy (Ancestors)

PeriodontitisPeriodontal DiseasesMouth DiseasesStomatognathic DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PyrrolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeptanoic AcidsFatty AcidsLipids

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor and head, department of periodontics

Study Record Dates

First Submitted

November 30, 2014

First Posted

March 11, 2015

Study Start

November 1, 2013

Primary Completion

July 1, 2014

Study Completion

July 1, 2014

Last Updated

March 11, 2015

Record last verified: 2014-11